What is the future of targeted therapy in rheumatology: Biologics or small molecules?

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Mócsai, Attila ^a,b   Kovács, László ^c   Gergely, Péter ^d  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Biologic therapies; Kinase inhibitors; Rheumatoid arthritis; Small molecule therapeutics; TNF antagonists; Tofacitinib

Indexed keywords

ABELSON KINASE; ADALIMUMAB; AMINOPTERIN; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; BCR ABL PROTEIN; C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DASATINIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HIGH DENSITY LIPOPROTEIN; IMATINIB; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR; LOW DENSITY LIPOPROTEIN; METHOTREXATE; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SUNITINIB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ANCA ASSOCIATED VASCULITIS; ANKYLOSING SPONDYLITIS; ARTERIAL STIFFNESS; ARTICLE; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; HUMAN; INFLAMMATORY DISEASE; INTRACELLULAR SIGNALING; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FUNCTION; LYMPHOCYTE SUBPOPULATION; OSTEOPOROSIS; PERSONALIZED MEDICINE; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; THERAPY EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 84897524513     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-12-43     Document Type: Article

References (54)

1. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002, 2:364-371. 10.1038/nri802, 12033742.
2. Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol 2013, 9:154-163. 10.1038/nrrheum.2013.8, 23419427.
3. Navarro-Millan I, Curtis JR. Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis. Curr Opin Rheumatol 2013, 25:384-390. 10.1097/BOR.0b013e32835fc62e, 23511719.
4. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817. 10.1182/blood-2008-07-077958, 19064740.
5. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005, 315:971-979. 10.1124/jpet.105.084145, 16002463.
6. Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010, 9:956-970. 10.1038/nrd3297, 21119733.
7. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009, 228:273-287. 10.1111/j.1600-065X.2008.00754.x, 2782696, 19290934.
8. Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010, 10:387-402. 10.1038/nri2765, 20467426.
9. Lowell CA. Src-family kinases: rheostats of immune cell signaling. Mol Immunol 2004, 41:631-643. 10.1016/j.molimm.2004.04.010, 15220000.
10. van Vollenhoven RF. Rheumatoid arthritis in 2012: progress in RA genetics, pathology and therapy. Nat Rev Rheumatol 2012, 2013:70-72.
11. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010, 363:1303-1312. 10.1056/NEJMoa1000500, 20879879.
12. Hammaker D, Firestein GS. Go upstream, young man: lessons learned from the p38 saga. Ann Rheum Dis 2010, 69:i77-i82. 10.1136/ard.2009.119479, 2911016, 19995751.
13. van Vollenhoven RF. Small molecular compounds in development for rheumatoid arthritis. Curr Opin Rheumatol 2013, 25:391-397. 10.1097/BOR.0b013e32835fd828, 23492738.
14. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S, Investigators TS. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006, 54:1063-1074. 10.1002/art.21655, 16572441.
15. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sorensen H, Zeidler H, Sieper J. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008, 67:340-345.
16. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88-96. 10.1136/ard.2008.105197, 3747519, 19297346.
17. Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EM, Churchman SM, Quinn M, Wakefield R, Conaghan PG, Ponchel F, Emery P. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?. Ann Rheum Dis 2010, 69:1636-1642. 10.1136/ard.2009.117341, 20421345.
18. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D. T2T Expert Committee Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637. 10.1136/ard.2009.123919, 3015099, 20215140, T2T Expert Committee.
19. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011, 186:4234-4243. 10.4049/jimmunol.1003668, 3108067, 21383241.
20. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS. ORAL Solo Investigators Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012, 367:495-507. 10.1056/NEJMoa1109071, 22873530, ORAL Solo Investigators.
21. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001, 93:178-193. 10.1093/jnci/93.3.178, 11158186.
22. Ospelt C, Gay S. Safety concerns on the development of novel therapeutic drugs. Arthritis Res Ther 2006, 8:112. 10.1186/ar2032, 1779448, 16968526.
23. Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M, Kunzler P, Enseleit F, Periat D, Hermann M, Nussberger J, Luscher TF, Corti R, Noll G, Ruschitzka F. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008, 117:2262-2269. 10.1161/CIRCULATIONAHA.107.734384, 18427133.
24. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B. ORAL Standard Investigators Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012, 367:508-519. 10.1056/NEJMoa1112072, 22873531, ORAL Standard Investigators.
25. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008, 58:2968-2980. 10.1002/art.23940, 18821691.
26. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register Control Centre Consortium Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007, 56:2905-2912. 10.1002/art.22809, 2435427, 17763428, British Society for Rheumatology Biologics Register Control Centre Consortium.
27. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011, 70:482-487. 10.1136/ard.2010.135871, 3058921, 21216812.
28. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, van der Meer JW, van Riel PL, Stalenhoef AF, Barrera P. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007, 66:1503-1507. 10.1136/ard.2006.066191, 2111626, 17472994.
29. Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, Radstake TR, Netea MG, Roest M, Stalenhoef AF. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2009, 68:868-872. 10.1136/ard.2008.092171, 18635596.
30. Heathfield SK, Parker B, Zeef LA, Bruce IN, Alexander MY. Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective. Clin Exp Rheumatol 2013, 31:225-233.
31. McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 2009, 6:410-417. 10.1038/nrcardio.2009.57, 19421244.
32. Khan F, Galarraga B, Belch JJ. The role of endothelial function and its assessment in rheumatoid arthritis. Nat Rev Rheumatol 2010, 6:253-261. 10.1038/nrrheum.2010.44, 20351705.
33. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, Kardassis D, Boumpas DT, Sidiropoulos PI. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 2012, 14:R141. 10.1186/ar3874, 3446524, 22691241.
34. Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, Dallinga-Thie GM, Levels JH, Kok M, Vos K, Tas SW, Tietge UJ, Müller N, Laudes M, Gerlag DM, Stroes ES, Tak PP. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis 2013, 229:174-181. 10.1016/j.atherosclerosis.2013.04.031, 23746537.
35. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Carlson TH, Delles C, Lee JS, Sattar N. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2013, doi:10.1136/annrheumdis-2013-204345.
36. Senel S, Kisacik B, Ugan Y, Kasifoglu T, Tunc E, Cobankara V. The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis. Clin Rheumatol 2011, 30:1369-1372. 10.1007/s10067-011-1782-6, 21618077.
37. Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P. Persistence and compliance of medications used in the treatment of osteoporosis-analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 2012, 50:315-322. 10.5414/CP201632, 22541835.
38. Braun J, Kastner P, Flaxenberg P, Wahrisch J, Hanke P, Demary W, von Hinuber U, Rockwitz K, Heitz W, Pichlmeier U, Guimbal-Schmolck C, Brandt A. MC-MTX.6/RH Study Group Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008, 58:73-81. 10.1002/art.23144, 18163521, MC-MTX.6/RH Study Group.
39. Emery P, Dorner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011, 70:2063-2070. 10.1136/ard.2010.148015, 22039166.
40. Wright S, Yelland M, Heathcote K, Ng SK, Wright G. Fear of needles-nature and prevalence in general practice. Aust Fam Physician 2009, 38:172-176.
41. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract 2007, 61:1922-1930. 10.1111/j.1742-1241.2007.01561.x, 17784852.
42. McInnes IB, Combe B, Burmester G. Understanding the patient perspective - results of the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) patient needs survey. Clin Exp Rheumatol 2013, 31:350-357.
43. Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM. Adherence in chronic disease. Annu Rev Nurs Res 2000, 18:48-90.
44. World Health Organization Adherence to Long-term Therapies: Evidence for Action 2003, Available at: http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf, World Health Organization.
45. Sawyer SM, Aroni RA. Sticky issue of adherence. J Paediatr Child Health 2003, 39:2-5. 10.1046/j.1440-1754.2003.00081.x, 12542804.
46. An X, Tiwari AK, Sun Y, Ding PR, Ashby CR, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res 2010, 34:1255-1268. 10.1016/j.leukres.2010.04.016, 20537386.
47. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480. 10.1056/NEJMoa020461, 12181401.
48. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214. 10.1056/NEJMoa025217, 12660384.
49. Jain A, Singh JA. Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy 2013, 5:265-299. 10.2217/imt.13.10, 3779683, 23444956.
50. O'Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol 2013, 9:173-182. 10.1038/nrrheum.2013.7, 23419429.
51. Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 2012, 12:464-470. 10.1016/j.coph.2012.06.008, 3419278, 22819198.
52. Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol 2012, 83:1136-1145. 10.1016/j.bcp.2011.12.024, 22209716.
53. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C. ORAL Step investigators Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013, 381:451-460. 10.1016/S0140-6736(12)61424-X, 23294500, ORAL Step investigators.
54. Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 2012, 24:335-341. 10.1097/BOR.0b013e32835190ef, 22357358.